of CKD stages, there was a statistically significant increase in the thickness of the heart walls and the size of the heart cavities.

We compared echocardiographic parameters of the heart in patients with different stages of CKD and the control group using the Scheffe’s test. The patients with stage I CKD differed from the control group by slightly increased EchoCG indices, but the differences were not statistically significant (p>0.05 for all parameters).

Of particular interest were the EchoCG parameters determined among patients with CKD stage III. They showed a significant increase in the thickness of left ventricular posterior wall (p=0.001) and the left ventricle end-diastolic diameter (p=0.037). Changes in the interventricular septum thickness, the size of the left atrium and the left ventricular systolic dimension were not statistically significant (p>0.05).

Patients with CKD stage V differed in a statistically significant increase in the size of the left atrium, the thickness of left ventricular posterior wall and interventricular septum (p<0.001) and a statistically significant increase left ventricular systolic and diastolic dimensions (p<0.05).

The analysis showed that the left ventricular mass, left ventricular mass index significantly increased with the progression of CKD stages (p<0.001). The left ventricular mass in patients with CKD stage V was significantly increased in 2,3 times in comparison with the control group.

Conclusions Structural-functional changes of the heart in children with CKD manifest left ventricular myocardial hypertrophy in the early stages and the addition of an increase in the left ventricular cavity in patients with CKD stage V.

Infantile hemangioma is the most common benign tumor of infancy, affecting 1–2% of infants. Hemangiomas of the airway constitute an even smaller percentage, but their management can be challenging due to the potential for life threatening airway compromise. A Subglotic hemangioma (SGH) makes up 1.5% of all congenital laryngeal anomalies, it is twice more common in females than males and have been linked to low birth weight and prematurity. It is during the early proliferative phase (1–3 months of life) that patients become symptomatic, developing characteristic stridor which may progress to respiratory distress. In this early stage, a SGH is often mistaken for a more common condition such as croup. The aim of this case is to underline what a recurrent dyspnea or laryngeal stridor in the first 6 months might hide.

Case report A 4 months-old-girl who was born at term of natural childbirth (birth weight 2.500 kg-SGA), presented with several weeks of unremitting stridor, substernal retractions. She was diagnosed to have bronchiolitis and she had been hospitalized twice in another hospital and treated with oral steroids and nebulized racemic epinephrine without significant improvement in her symptoms; Than she had been sent to our hospital. She had intercostal and substernal retractions. Both lungs had equal contribution to respiration, respiratory sounds were coarse and she had both inspiratory and expiratory stridor which were more obvious on bilateral sibilant rales, and inspiratory phase. She also had wheezing. Laboratory tests, echocardiogram and electrocardiogram were normal. Her follow-up showed that she was not responding to treatment and her respiratory distress was increasing, thus she had a laryngoscopy that did not reveal any clear structural abnormalities, and performed a CT scan of the neck, which showed a solid tissue of low intensity on T1-weighted spin-echo images and of hyperintensity on T2-weighted spin-echo images (6x8 mm), compatible with SGH. After her workup was complete, she received an initial dose of propranolol at 0.5 mg/kg, which was increased to 2 mg/kg, and no adverse effects were noted. SGH is a rare but potentially life-threatening disease. A high index of suspicion is vital for the early, accurate diagnosis of this disease. Propranolol treatment has many advantages, it is non-invasive and it has a low complication rate; thus, the use of propranolol as a first-line treatment for SGH is proposed.